News

Teva Social Media Platforms Seek to Help HD Patients Manage Chorea

The pharmaceutical company Teva is turning to social media to help people with Huntington’s disease (HD) to improve the management of chorea — a hallmark motor symptom that an estimated 90% of patients with the neurodegenerative disorder will develop. The company, fully Teva Pharmaceutical Industries, has established…

Dosing Paused in Phase 2 Branaplam Trial Due to Possible Side Effects

Due to possible side effects, dosing is being paused in the Phase 2 VIBRANT-HD clinical trial of oral branaplam (LMI070) in adults with Huntington’s disease. A scheduled assessment found “early signs” that “branaplam might be causing peripheral neuropathy,” a condition marked by pain or numbness in the extremities caused by damage…